Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company that describes itself as a leading provider of autoimmune diagnostics and autoimmune testing solutions. Based in San Diego County, California, Exagen focuses on chronic and debilitating autoimmune conditions, particularly autoimmune rheumatic diseases. Its news flow reflects both its operational performance and its scientific and clinical activities in this specialized area.
Company news frequently covers financial results and operational updates, including quarterly earnings releases, preliminary annual results, and related guidance. These updates often discuss revenue trends, test volume for the AVISE CTD panel, average selling price metrics, and cash and cash equivalents, giving investors insight into Exagen’s commercial progress as an autoimmune diagnostics provider.
Exagen’s news also highlights developments in its testing portfolio and research programs. The company reports on enhancements to AVISE CTD, such as the commercial launch of seronegative rheumatoid arthritis markers for anti-PAD4, and on scientific milestones like the acceptance of multiple abstracts at the American College of Rheumatology’s annual meeting. These abstracts address topics including urinary biomarker panels for lupus nephritis, kidney-specific biomarker panels, T cell biomarkers, and multianalyte lupus risk scores.
Additional announcements include participation in healthcare and diagnostics investor conferences and leadership appointments, such as the addition of a Chief Scientific Officer and new board members with experience in life sciences and medical technology. Together, these news items give a view into Exagen’s financial performance, scientific focus, and corporate development. Investors and observers can use the XGN news page to follow how the company reports on its autoimmune testing business, research activities, and strategic initiatives over time.
Exagen Inc. (Nasdaq: XGN) announced a collaborative clinical trial with Duke University to study biomarkers in lupus patients. This prospective study aims to evaluate the AVISE panel and Cell-Bound Complement Activation Products (CB-CAPs) to differentiate between Type 1 and Type 2 systemic lupus erythematosus (SLE). By integrating patient-reported measures, the trial seeks to enhance personal medicine approaches for lupus care, potentially improving patient outcomes. Exagen aims to optimize therapeutic interventions for autoimmune diseases through its proprietary technologies.
Exagen Inc. (Nasdaq: XGN) announced that Ron Rocca, President and CEO, will present at the William Blair 40th Annual Growth Stock Conference on June 9 at 1:20 PM CDT. This year's conference will be virtual, and a live webcast of the presentation will be accessible via the Exagen investor relations website. A replay will be available about one hour after the event concludes. Exagen focuses on transforming care for patients with autoimmune diseases through innovative testing products, including those based on proprietary CB-CAPs technology.
Exagen Inc. (Nasdaq: XGN) reported its financial results for Q1 2020, showing total revenue of $9.6 million, up from $9.3 million in Q1 2019. The company delivered 27,126 AVISE® CTD tests, a 13% increase over the previous year, while the number of ordering healthcare providers grew by 28% year-over-year. However, operating expenses rose to $14.8 million, leading to a net loss of $5.6 million, compared to $2.7 million in Q1 2019. Cash reserves stood at approximately $68.6 million as of March 31, 2020.
Summary not available.